New MRI-Guided radiation aims to zap sarcomas with pinpoint accuracy
NCT ID NCT06436612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a precise radiation technique called MRI-guided stereotactic body radiation therapy (SBRT) for people with sarcomas in the abdomen or pelvis. The radiation is given over 5 days, followed by surgery within 12 weeks. The goal is to safely deliver high-dose radiation to the tumor while sparing healthy organs. Researchers will track side effects and tumor control for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MRI-guided stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this approach could offer a more precise, safer way to treat sarcomas in the abdomen and pelvis, potentially reducing side effects and improving tumor control.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment still requires surgery afterward, and there is a risk of radiation-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINOPELVIC SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States